← Back to Search

Behavioral Intervention

Mobile App Support for Breast Cancer Treatment Adherence

N/A

Waitlist Available

Led By Amelie G. Ramirez, DrPH

Research Sponsored by The University of Texas Health Science Center at San Antonio

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

English and Spanish speaking adult patients, 18 years of age and older who are diagnosed with hormone receptor-positive breast cancer and prescribed endocrine hormonal treatment (EHT)

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up outcome will be assessed at 3 points: baseline, 3 and 6 months

Awards & highlights

Study Summary

This trial will develop and test a mobile app to improve adherence to endocrine hormonal therapy (EHT) among breast cancer patients. The app will be personalized and interactive, and will be used in combination with patient navigation.

Who is the study for?

This trial is for English and Spanish speaking adults over 18 with hormone receptor-positive breast cancer who are prescribed EHT. Participants must be able to consent, own a cell phone, send/receive texts, and access the internet. It excludes those without smartphones or unable to understand consent due to disabilities.Check my eligibility

What is being tested?

The study tests if a bilingual mobile app combined with patient navigation can help breast cancer patients stick to their endocrine hormonal therapy (EHT). The goal is to see if this approach lowers the risk of recurrence by improving medication adherence.See study design

What are the potential side effects?

Since this trial focuses on an educational tool rather than a medical treatment, there are no direct side effects from drugs being tested. However, participants may experience stress or anxiety related to technology use or managing their treatment regimen.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 or older, speak English or Spanish, and have hormone receptor-positive breast cancer treated with hormone therapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ outcome will be assessed at 3 points: baseline, 3 and 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~outcome will be assessed at 3 points: baseline, 3 and 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and outcome will be assessed at 3 points: baseline, 3 and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Adherence to EHT

Secondary outcome measures

Change in Anxiety

Change in Quality of Life

Usability and satisfaction with the mobile app

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Mobile phone app + patient navigationExperimental Treatment1 Intervention

Patients assigned to the intervention group (60) will: 1) use the personalized mobile phone app in their preferred language for a duration of 6 months; and 2) receive assistance from a patient navigator. They will also continue to receive the usual EHT care provided at the MCC's breast clinic.

Group II: Usual careActive Control1 Intervention

Patients assigned to the control (usual care) group (60) will receive the usual EHT care and materials offered at the MCC's breast clinic.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor

452 Previous Clinical Trials

91,306 Total Patients Enrolled

14 Trials studying Breast Cancer

1,432 Patients Enrolled for Breast Cancer

Amelie G. Ramirez, DrPHPrincipal InvestigatorThe University of Texas Health Science Center at San Antonio

1 Previous Clinical Trials

77 Total Patients Enrolled

1 Trials studying Breast Cancer

77 Patients Enrolled for Breast Cancer

Media Library

Mobile phone app + patient navigation (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT02850939 — N/A

Breast Cancer Research Study Groups: Mobile phone app + patient navigation, Usual care

Breast Cancer Clinical Trial 2023: Mobile phone app + patient navigation Highlights & Side Effects. Trial Name: NCT02850939 — N/A

Mobile phone app + patient navigation (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02850939 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it still possible to join the current clinical trial?

"The entry posted on clinicaltrials.gov confirms that, as of April 26th 2022, this medical trial is not recruiting participants. Initially posted to the site on May 3rd 2021, 2603 other studies are actively looking for volunteers right now."

Answered by AI

Recent research and studies

Contemporary Clinical Trials CommunicationsJournal

Improving Adherence to Endocrine Hormonal Therapy Among Breast Cancer Patients: Study Protocol for a Randomized Controlled Trial

Chalela, P., E. Munoz, D. Inupakutika, S. Kaghyan, D. Akopian, V. Kaklamani, K. Lathrop, and A. Ramirez. 2018. “Improving Adherence to Endocrine Hormonal Therapy Among Breast Cancer Patients: Study Protocol for a Randomized Controlled Trial”. Contemporary Clinical Trials Communications. Elsevier BV. doi:10.1016/j.conctc.2018.10.001.

clinicaltrials.govStudy

Improving Adherence to EHT Among Breast Cancer Patients

2021. "Improving Adherence to EHT Among Breast Cancer Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02850939.

All > Breast Cancer Austin